

Press Release



Notice regarding the transfer of uterine contraction suppressant " Magsent®" and eclampsia suppressant/therapeutic agent "MAGNESOL®"

TOKYO, October 1st, 2019 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that as of October 1st 2019, ASKA and TOA Biopharma Co., Ltd (Head Office: Shibuya-ku, Tokyo, President: Tomohide Masuda, hereinafter "TOA") have entered into a business transfer agreement regarding the agents of " Magsent® Injection 100mL", " Magsent® Injection Syringe 40mL(generic name: Magnesium Sulfate Hydrate · Glucose)" which are indicated for preventing uterine contraction, and "IV MAGNESOL® (generic name: Magnesium Sulfate Hydrate · Glucose)" which is indicated for the prevention and treatment of eclampsia, both agents which are manufactured and marketed by TOA.

Under this agreement, the rights related to manufacturing and marketing approval for both agents will be transferred to ASKA from TOA beginning from February 1st, 2020. In regards to maintaining a steady product supply, both products by TOA will continue to be distributed for an amount of time after the transfer has taken place.

TOA and ASKA will work together to facilitate a smooth transition regarding sale activities for "Magsent" and "MAGNESOL", and will continue to supply both products as well as promote product information and appropriate product use that meets medical needs.

[Inquiries regarding this matter]
TOA Biopharma Co., Ltd.
TEL: +81-3-3375-0511
ASKA Pharmaceutical Co., Ltd.
TEL: +81-3-5484-8366